Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128482 | 0.92 | SPHK1 (0.40) | SPHK1SPHK2 | |
| SCHEMBL19903894 | 0.88 | CACNA1G (0.39) | CACNA1GSIGMAR1SLC6A12TMEM97MCHR1 | |
| SCHEMBL20128487 | 0.85 | SPHK1 (0.40) | SIGMAR1SPHK1SPHK2 | |
| SCHEMBL20128485 | 0.78 | WNT3 (0.36) | SPHK1SPHK2 | |
| SCHEMBL20128496 | 0.78 | BCHE (0.42) | CACNA1GSIGMAR1SLC6A12TMEM97MCHR1 | |
| SCHEMBL20128497 | 0.77 | SPHK2 (0.44) | CACNA1GSIGMAR1SLC6A12TMEM97MCHR1 | |
| SCHEMBL9891867 | 0.70 | GBA1 (0.47) | SIGMAR1SPHK1SPHK2SLC18A3 | |
| SCHEMBL24926340 | 0.70 | ACHE (0.45) | SPHK1SPHK2ACHE | |
| SCHEMBL17805425 | 0.70 | TACR1 (0.46) | SPHK1SPHK2 | |
| SCHEMBL18801726 | 0.70 | TACR1 (0.46) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | CACNA1G 2904/4885SIGMAR1 3221/4885SLC6A12 4618/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | CACNA1G 2904/4885SIGMAR1 3221/4885SLC6A12 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.